The statement comes after a misleading article was published in the Vancouver Sun on February 25, and reprinted in four other CanWest newspapers, which may erroneously lead individuals to question the effectiveness of COLD-fX®.

"We believe the article contains errors, misleading information, improper context, unfamiliarity with cold and flu clinical research, and a pharmaceutical predisposition to curative care rather than preventative care," said Dr. Jacqueline Shan, President, CEO and Chief Scientific Officer of CV Technologies. "The Vancouver Sun's article may have the public unnecessarily questioning COLD-fX®, when in fact, they have no reason to. Our product is evidence-based and clinically researched to the highest standards, and the trials in question were subjected to a rigorous peer review process and were published in two highly respected medical journals."

The article, written by a business columnist with little background in the science of colds and flu relied exclusively on the opinions of two academics who are not experts in cold and flu research or clinical practice. Neither of these two individuals interviewed for the article has demonstrated real experience in drug development.

"COLD-fX® works and we can prove it," said Dr. Shan. "These clinical trials in question were conducted to the highest standards: they were double-blind, placebo-controlled and randomized and regulated by either Health Canada or the U.S. FDA (Food and Drug Administration).

"The totality of evidence demonstrated through seven peer reviewed publications further supports our position that COLD-fX® is proven to prevent colds and flu", said Dr. Shan. "In addition, we estimate that as many as 21 national and international experts, who regularly review research for medical journals in both Canada and the United States, have reviewed the science behind COLD-fX® and recommended it for publication."

The Vancouver Sun did not include quotes on the study results from any of the authors of the COLD-fX® trials, or from any of the editors of the peer-reviewed medical journals. The editors had expert scientists critique the studies, who in turn accepted the scientific validity of these clinical studies. These trials provide the proof that COLD-fX® does in fact work by showing statistical differences between the placebo and COLD-fX® treatments.

CREDENTIALS OF SOME PAST AND PRESENT SENIOR CLINICAL INVESTIGATORS OF COLD-fX®

Dr. Gerry Predy, MD, received his doctorate in medicine from the University of Alberta in 1976 and holds a Fellowship in the Royal College of Physicians and Surgeons (Canada) in Community Medicine. Since 1996 he's been the MOH for the Capital Health Region in Alberta - the largest integrated academic health region in Canada. He supervises 170 public health nurses, inspectors and health care workers involved in public health education. He's an associate professor at the University of Alberta, and the Director of the Northern Alberta Trials and Evaluation Centre and has conducted research in a number of public health areas. He's also the former chair of the Alberta Council of Officers of Health. He was a co-clinical investigator for a trial involving COLD-fX® published in the October 2005 edition of the Canadian Medical Association Journal.

Dr. Tapan Basu, Ph.D. studied in the Department of Nutritional Biochemistry at the University of London and received his doctorate from the University of Surrey in 1971. He has written extensively on nutrition and pharmacology including 6 books and 158 papers and abstracts. He is or has been a member of advisory boards for professional publications such as the British Journal of Nutrition and has played a key role in international conferences on clinical nutrition in six different countries. He holds 9 awards or honours for his work and has received research grants from five countries. He holds memberships in 12 professional societies including the British Society of Surgical Oncology and is a fellow of the American College of Nutrition. He was a co-clinical investigator for a trial involving COLD-fX® published in the October 2005 edition of the Canadian Medical Association Journal.

Dr. Janet McElhaney, MD, FRCPC received her doctorate in medicine from the University of Alberta in 1986 and holds a Fellowship in the Royal College of Physicians and Surgeons (Canada). She is a specialist in geriatric medicine and is the chair of department of geriatric medicine, University of British Columbia. She is the recipient of 17 honours, awards and scholarships including one from each of both the American and Canadian Geriatrics Societies. She has taught at four universities over the past 13 years including the University of Connecticut where she held an appointment in the Centre for Immunotherapy for Cancer and Infectious Diseases and was cross-appointed in the University's Centre on Aging. She has been or is a member or chair of 16 university committees, 7 professional societies/associations and two professional journals. She has written extensively on respiratory diseases and geriatric medicine including 67 papers, abstracts and book chapters. She has lectured or presented abstracts in seven countries and has done research for 9 pharmaceutical companies. She was the clinical investigator for a trial involving COLD-fX® published in the January 2004 edition of the Journal of the American Geriatrics Society.

Dr. Allan Donner, PhD was the chair of the Department of Epidemiology and Biostatistics, University of Western Ontario for 15 years beginning in 1987 with a special emphasis on Community Medicine and Population Health. He is a co-author of the text "Design and Analysis of Cluster Randomization Trials in Health Research". He served on this steering committee of multi-national trials sponsored by the World Health Organization and the European Commission, is a consultant to the international Vaccine Institute based in Korea, and is a member of the Expert Advisory Committee on Bioavailability and Bioequivalence at Health Canada. He has presented invited talks and workshops for the Society for Clinical Trials, the Drug Information Association and the Biometric Society. He is a fellow of the American Statistical Association and was president of the Biostatistics Section of the Statistical Society of Canada in 1991-1992. He currently holds research grants from the Canadian Institute of Health (CIHI), the Natural Sciences & Engineering Research Council of Canada and the Ontario Ministry of Health.

Dr. Andrew Simor, MD, FRCPC received his doctorate in medicine from the University of Toronto in 1976 and holds a Fellowship in the Royal College of Physicians and Surgeons (Canada) and the American College of Physicians-American Society of Internal Medicine. He is a specialist in infectious diseases, with expertise in geriatrics. He holds 7 appointments including Head, Department of Microbiology, Sunnybrook and Women's College Health Sciences Centre. He has taught at McMaster University and the University of Toronto and was for 10 years Director of the university's residency training program in microbiology and for 5 years chair of the Board of Examiners, Infectious Diseases, RCPSC. He's been or currently is chair/member of 28 professional committees. He belongs or has belonged to 11 professional societies or organizations. He has received various other honours or awards including the U of T's Teaching Institutional Award in Microbiology. He has written extensively on infectious diseases including 185 papers, 27 non-peer reviewed publications, and 33 reviews, chapters or monographs, and since 1982 published alone or with colleagues 370 papers or abstracts. He has been principal or co-investigator of 32 research projects for the Centre for Diseases Control (CDC), Health Canada, the Medical Research Council of Canada, and Canadian Institutes of Health Research (CIHR)

CV Technologies president, CEO & Chief Scientific Officer

Dr. Jacqueline Shan, PhD, DSc. is the co-discoverer of COLD-fX®. She holds two doctorates, is recognized by universities in three countries and is a member of the distinguished Chinese Academy of Medical Sciences. Awarded PhD with distinction in Physiology at U of Alberta, Canada in 1992, Doctor of Science (D.Sc) in Pharmacology from Peking Union Medical College in Beijing in 1993. She is an adjunct professor, University of Alberta, Distinguished Visiting Investigator, National Research Institute of Chinese Medicine in Taiwan, Visiting Professor/Peking Union Medical College and Visiting Associate Professor, University of Hong Kong. She authored/co-authored 50 peer reviewed scientific papers. She entered industry in 1992 by co-founding two biotechs - CV Technologies Inc. and HerbTech Inc. both of Edmonton, Alberta. Canada. She discovered /co-discovered 10 U.S. & PCT patented products. Dr. Shan is a nationally/internationally recognized speaker and the past/present member of 20 government industry, science and research bodies and was recently appointed to the Alberta Life Sciences Institute chaired by the Alberta Minister of Innovation and Science.

NATIONAL/INTERNATIONAL EXPERTS WHO HAVE COMMENTED ON CLINICAL TRIALS INVOLVING COLD-fX®

Excerpt from a column in the Montreal Gazette which talks about the fact that a quarter of current prescription drugs come from plants and the lack of standardization in natural health products - Dr. Schwarcz singles out COLD-fX® as an exception.

"Of course, you will note that the word "may" appear very often in discussions of herbal treatments because hard scientific evidence is elusive. But in one interesting case, we may be able to remove the may. Maybe.

Ginseng has long been associated with a number of fanciful health benefits including increased energy, improved mental function, and a vitalization of the immune system. Now a Canadian company, CV Technologies of Edmonton, has demonstrated through sound research that there is something to the improved immune function claim.

A specific preparation of North American ginseng, containing a standardized amount of certain polysaccharides that are thought to be the active ingredients, has been shown in clinical trials to have an effect on the common cold. It isn't quite the Holy Grail, but "COLD-fX®" in a proper controlled double blind trial reduced the frequency and severity of the common cold.

Dr. Joe Schwarcz, writing in the Montreal Gazette, Dec 4, 2005.

Dr. Schwarcz is Director of McGill University's Office for Science and Society and a medical commentator on CJAD-Radio, Montreal and CFRB-Radio, Toronto and host of a weekly one hour show each Sunday on these stations called, "The Dr. Joe Schwarcz Show".

Commenting on COLD-fX®: "It looks like a good product and something people should pay attention to". Comments after taking COLD-fX: "I swear that's the mildest cold I've had in years."

Dr. Art Hister on "House Calls" on CKNW-Radio Vancouver, Nov 12, 2005

Dr. Hister is an author and medical commentator who was selected Canada's top public health educator by the Canadian Public Health Association. He is the host of the weekly radio show - "House Calls", which airs on 8 radio stations in 4 provinces.



"I think it's intriguing. It's provocative. They had a positive result which is frankly more than I had expected."

Dr. William Schaffner, ABC-TV's Good Morning America, Oct 25, 2005

Dr. William Schaffner, Chairman of the Department of Preventive Medicine and Professor Infectious Diseases in the Department of Medicine at Vanderbilt University's School of Medicine. Professor Schaffner is an International flu expert and member of the Centres for Disease Control and Prevention's Advisory Committee on Immunization Practices and a consultant in communicable diseases control for WHO, the American Hospital Association and the American College of Physicians. He serves on the editorial board of 3 medical journals and authored or co-authored 230 published studies, reviews and book chapters on infectious diseases. Dr. Schaffner is a graduate of Yale and Cornell.

"The results look pretty good."

Dr. Norman Farnsworth, Newsday, Oct 25, 2005

Dr. Norman Farnsworth is a member of Health Canada's Expert Advisory Committee on Natural Health Products. He's Director of the Program for Collaborative Research/Pharmaceutical Sciences. Department of Chemistry and Director of the UIC/NIH Dietary Supplements Research Centre at the University of Illinois, Director of WHO's Collaborating Centre for Traditional Medicine. He is credited with designing a worldwide database called NAPRALERT that compiles scientific literature on the safety and efficacy of herbal medicines, plants, marine organisms and fungi.

"In my judgment there is no doubt that COLD-fX is effective in lowering the incidents of colds."

Dr. Tapan Basu, Canadian Researcher, University of Alberta Professor Emeritus, on CTV News, Oct 25, 2005

"This may well be the first product of its kind that has some benefit in either shortening the length of the common cold and perhaps even preventing it."

Dr. Andrew Simor, Chief of Microbiology, Sunnybrook & Women's College Hospital, Toronto, CBC-TV Network, Oct 5, 2005

"This is a good study. It does tell us something about this product and prevention."

Dr. Heather Boon, Assistant Professor, Faculty of Pharmacy, University of Toronto, CTV NewsNet, Oct 24,

"The methods of this study were strong and they protect against bias."
"This may be the only formulation that works so you can't assume that any ginseng from any health food store is going to do the trick."
"For people who like to avoid medication and who are willing to take a pill throughout the entire season this does show it's possible to prevent a cold. That's an interesting advance. You know it's been axiomatic that we could put people on the moon, but we can't prevent a cold. Maybe we're moving in that direction. That's exciting."

Dr. David Katz, ABC-TV's Good Morning America, Oct 25, 2005

Dr. Goldman concluded that the results were ' statistically significant.'

Dr. Brian Goldman, CBC-Radio's long-time medical commentator, over CBC-Radio, Halifax's "Mainstreet" Oct 27, 05

"(CV technologies') initial trials seem to indicate that it may be effective in preventing a whole range of respiratory viruses."

Dr. Robert Strang, Halifax, Chief Medical Officer of Health/Halifax Chronicle Herald,
Mar 15 /05

"It's obviously not going to be the cure for the common cold. There are so many factors involved in why people get colds that I think we will probably never see a cure. This study does show some effect of this product."

Dr. Gerry Predy, Edmonton Chief Medical Officer of Health, CFCN-TV, Calgary
Oct 5, 2004

ABOUT CV TECHNOLOGIES INC.

CV Technologies was founded in 1992. It aims to become a global leader in the development and commercialization of evidence based, natural medicines for disease prevention and health maintenance. CVT's lead product, COLD-fX®, strengthens the immune system and is widely used as a leading anti-cold, anti-flu, therapeutic. COLD-fX® is patented. Its unique mechanism of action is developed and standardized according to the Company's ChemBioPrint® technology. The CBP® process precisely identifies the chemical profile and biological activity of multi-active components in the natural compound. The CBP® process provides a manufacturing protocol that ensures each batch of compound delivers verifiable and provable health benefits.

www.cvtechnologies.com
www.cold-fx.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.